Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIT | P10721 | 1/20 | 0.52 |
| ▸ | BRAF | P15056 | 2/20 | 0.51 |
| ▸ | ABL1 | P00519 | 2/20 | 0.48 |
| ▸ | IKBKB | O14920 | 1/20 | 0.46 |
| ▸ | CHUK | O15111 | 1/20 | 0.46 |
| ▸ | IKBKG | Q9Y6K9 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.45 |
| ▸ | NAMPT | P43490 | 2/20 | 0.44 |
| ▸ | SRC | P12931 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | ATR | Q13535 | 2/20 | 0.43 |
| ▸ | SUV39H1 | O43463 | 1/20 | 0.43 |
| ▸ | GLA | P06280 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5995511 | 0.90 | POLB (0.55) | KITBRAFIKBKBCHUKIKBKG | |
| SCHEMBL5996051 | 0.89 | ABL1 (0.55) | KITBRAFABL1IKBKBCHUK | |
| SCHEMBL5994762 | 0.88 | ABL1 (0.53) | KITBRAFABL1IKBKBCHUK | |
| SCHEMBL5999296 | 0.80 | KIT (0.54) | KITBRAFABL1IKBKBCHUK | |
| SCHEMBL5998218 | 0.79 | BTK (0.39) | ABL1SRC | |
| SCHEMBL5997421 | 0.79 | SRC (0.57) | KITBRAFABL1IKBKBCHUK | |
| SCHEMBL5996926 | 0.79 | LCK (0.61) | KITBRAFABL1IKBKBCHUK | |
| SCHEMBL2497661 | 0.77 | BRAF (0.60) | KITBRAFIKBKBCHUKIKBKG | |
| SCHEMBL5996220 | 0.75 | SRC (0.56) | ABL1SRCALDH1A1 | |
| SCHEMBL5997190 | 0.74 | SRC (0.56) | BRAFABL1SRCPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110243999-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF OCULAR DISORDERS | TARGEGEN INC. | 2011-10-06 | — | — | US | disclosed |
| US-20060247250-A1 | Pyrimidine inhibitors of kinases | TARGEGEN, INC. (US) | 2006-11-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060247250-A1 | Pyrimidine inhibitors of kinases | DTYMK, SRC, DCK | KIT 209/4885BRAF 125/4885ABL1 12/4885 |
| US-20110243999-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF OCULAR DISORDERS | AQP3, AQP1, AQP4 | KIT 1800/4885BRAF 328/4885ABL1 4620/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.